{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T20:27:11Z","timestamp":1778531231801,"version":"3.51.4"},"reference-count":34,"publisher":"American Society of Hematology","issue":"24","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Predominantly antibody deficiencies have an estimated prevalence of &amp;gt;1 in 25\u2009000. Their classical phenotype entails the association of autoimmune manifestations with increased susceptibility to infections. Up to 8% of these patients ultimately develop immune thrombocytopenic purpura (ITP). Reducing the risk for infections and considering nonimmunosuppressive treatments, such as thrombopoietin receptor agonists (TPO-RAs), are important considerations for these patients. This nationwide retrospective case series assessed the outcomes and safety of TPO-RAs as treatment for ITP in adults diagnosed with predominantly antibody deficiencies. Response and complete response to treatment were defined as platelet count reaching 30\u00a0\u00d7 109\/L and 100\u00a0\u00d7 109\/L, respectively. We analyzed data from 28 patients. The median follow-up time after introduction of the first TPO-RAs was 33\u00a0months (range, 2\u00a0weeks to 10.6 years). After 6\u00a0weeks of follow-up, response was achieved in 24 of the 28 patients (85.7%), and among those, 21 patients (75%) displayed a complete response. At the last available follow-up visit, only 7 patients (25%) needed second-line therapies for ITP, and among those, only 5 patients (17.9%) received immunosuppressants. Only 3 patients (10.7%) reported laboratory-confirmed hepatobiliary adverse events of light or mild severity and 3 patients (10.7%) reported thrombotic events. In conclusion, TPO-RAs seemed to be an effective and safe option of treatment in these case series. Our results suggest that eltrombopag or romiplostim should be considered as second-line therapy for ITP related to predominantly antibody deficiencies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014370","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T20:14:22Z","timestamp":1727727262000},"page":"6171-6182","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of TPO receptor agonists in treatment of ITP associated with predominantly antibody deficiencies"],"prefix":"10.1182","volume":"8","author":[{"given":"Margaux","family":"Soulard","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, University Hospital of Rennes, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Galicier","sequence":"additional","affiliation":[{"name":"2Department of Clinical Immunology, and Immunodeficiencies Center, Saint-Louis Hospital, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0030-8094","authenticated-orcid":false,"given":"Nizar","family":"Mahlaoui","sequence":"additional","affiliation":[{"name":"3Department of Pediatric Immunohematology and Rheumatology, Necker Hospital Group, Paris, France"},{"name":"4Center of Reference for Hereditary Immunodeficiency Disorders, Necker Hospital Group, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2136-6178","authenticated-orcid":false,"given":"Claire","family":"Fieschi","sequence":"additional","affiliation":[{"name":"2Department of Clinical Immunology, and Immunodeficiencies Center, Saint-Louis Hospital, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8887-3233","authenticated-orcid":false,"given":"Samuel","family":"Deshayes","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine, University Hospital of Caen, Caen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Gobert","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine, University Hospital of St Antoine, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0740-2419","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Gourguechon","sequence":"additional","affiliation":[{"name":"7Department of Clinical Hematology and Cellular Therapy, University Hospital of Amiens, Amiens, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Henique","sequence":"additional","affiliation":[{"name":"8Department of Internal Medicine, University Hospital of Tours, Tours, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0454-0840","authenticated-orcid":false,"given":"Sebastien","family":"Humbert","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine, University Hospital of Besan\u00e7on, Besan\u00e7on, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2875-6048","authenticated-orcid":false,"given":"Carole","family":"Lacout","sequence":"additional","affiliation":[{"name":"10Department of Internal Medicine, University Hospital of Angers, Angers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5883-1825","authenticated-orcid":false,"given":"Ronan","family":"Le Calloch","sequence":"additional","affiliation":[{"name":"11Department of Hematology Inpatient Care, Hospital of Quimper, Quimper, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Michel","sequence":"additional","affiliation":[{"name":"12Department of Internal Medicine, Henri Mondor University Hospital, and Center of Reference for Autoimmune Cytopenias in Adults, Assistance Publique-H\u00f4pitaux de Paris, Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2619-0952","authenticated-orcid":false,"given":"Marie-lea","family":"Piel-julian","sequence":"additional","affiliation":[{"name":"13Department of Internal Medicine, University Hospital of Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7500-9323","authenticated-orcid":false,"given":"Jean Fran\u00e7ois","family":"Viallard","sequence":"additional","affiliation":[{"name":"14Department of Internal Medicine and Infectious Diseases, University Hospital of Bordeaux, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Lescoat","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, University Hospital of Rennes, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6023-5990","authenticated-orcid":false,"given":"Bertrand","family":"Godeau","sequence":"additional","affiliation":[{"name":"12Department of Internal Medicine, Henri Mondor University Hospital, and Center of Reference for Autoimmune Cytopenias in Adults, Assistance Publique-H\u00f4pitaux de Paris, Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoinette","family":"Perlat","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, University Hospital of Rennes, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"issue":"7","key":"2024122313404900300_bib1","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J\u00a0Clin Immunol"},{"issue":"6","key":"2024122313404900300_bib2","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jaip.2019.02.004","article-title":"The European Society for Immunodeficiencies (ESID) registry working definitions for the clinical diagnosis of inborn errors of immunity","volume":"7","author":"Seidel","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"7","key":"2024122313404900300_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.revmed.2020.12.015","article-title":"Les d\u00e9ficits immunitaires communs variables (DICV): partie 2. Mise \u00e0 jour clinique et th\u00e9rapeutique","volume":"42","author":"Viallard","year":"2021","journal-title":"Rev Med Interne"},{"issue":"1","key":"2024122313404900300_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaut.2010.10.002","article-title":"Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study","volume":"36","author":"Boileau","year":"2011","journal-title":"J\u00a0Autoimmun"},{"issue":"1","key":"2024122313404900300_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10875-017-0456-9","article-title":"Autoimmune cytopenias and associated conditions in CVID: a report from the USIDNET registry","volume":"38","author":"Feuille","year":"2018","journal-title":"J\u00a0Clin Immunol"},{"key":"2024122313404900300_bib6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fimmu.2020.00149","article-title":"Non-infectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis","volume":"11","author":"Ho","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"2024122313404900300_bib7","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an International Working Group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2024122313404900300_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12185-011-0886-8","article-title":"Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized phase III clinical trial","volume":"94","author":"Shirasugi","year":"2011","journal-title":"Int J Hematol"},{"issue":"20","key":"2024122313404900300_bib9","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2024122313404900300_bib10","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"9664","key":"2024122313404900300_bib11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet Lond Engl"},{"issue":"9763","key":"2024122313404900300_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"issue":"23","key":"2024122313404900300_bib13","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"issue":"9610","key":"2024122313404900300_bib14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"2024122313404900300_bib15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.revmed.2019.02.006","article-title":"Traitement du PTI et de l\u2019AHAI au cours du DICV : revue syst\u00e9matique de la litt\u00e9rature","volume":"40","author":"Lacombe","year":"2019","journal-title":"Rev Med Interne"},{"issue":"4","key":"2024122313404900300_bib16","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2011.08880.x","article-title":"Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients","volume":"155","author":"Gobert","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"2024122313404900300_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/cei.12039","article-title":"Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients","volume":"172","author":"Wong","year":"2013","journal-title":"Clin Exp Immunol"},{"issue":"5","key":"2024122313404900300_bib18","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s10875-016-0282-5","article-title":"Use of thrombopoietin-receptor agonist in CVID-associated immune thrombocytopenia","volume":"36","author":"Carrabba","year":"2016","journal-title":"J\u00a0Clin Immunol"},{"issue":"1","key":"2024122313404900300_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00277-021-04637-2","article-title":"Eltrombopag treatment of patients with secondary immune thrombocytopenia: retrospective EHR analysis","volume":"101","author":"Patwardhan","year":"2022","journal-title":"Ann Hematol"},{"key":"2024122313404900300_bib20","unstructured":"Chapel\n              H\n            \n          . Common variable immunodeficiency disorders (CVID) \u2014 diagnoses of exclusion, especially combined immune defects | EndNote click. Accessed 2 June 2024. https:\/\/click.endnote.com\/viewer?doi=10.1016%2Fj.jaip.2016.09.006&token=WzMxNzY0NjksIjEwLjEwMTYvai5qYWlwLjIwMTYuMDkuMDA2Il0.Et_js3ENEUXzjlYubBGDjyEgxB4."},{"issue":"7","key":"2024122313404900300_bib21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.revmed.2021.03.328","article-title":"Les d\u00e9ficits immunitaires communs variables (DICV) : partie 1 : \u00e9volution des crit\u00e8res diagnostiques et des connaissances g\u00e9n\u00e9tiques","volume":"42","author":"Fieschi","year":"2021","journal-title":"Rev Med Interne"},{"issue":"2","key":"2024122313404900300_bib22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.clim.2010.02.021","article-title":"The French national registry of primary immunodeficiency diseases","volume":"135","author":"CEREDIH The French PID study group","year":"2010","journal-title":"Clin Immunol"},{"issue":"6","key":"2024122313404900300_bib23","first-page":"829","article-title":"Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count","volume":"90","author":"Khellaf","year":"2005","journal-title":"Haematologica"},{"issue":"4","key":"2024122313404900300_bib24","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.12169","article-title":"Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)","volume":"160","author":"Bussel","year":"2013","journal-title":"Br J Haematol"},{"key":"2024122313404900300_bib25","volume-title":"StatPearls","author":"Chapman","year":"2024"},{"issue":"5","key":"2024122313404900300_bib26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S2468-1253(19)30047-0","article-title":"Porto-sinusoidal vascular disease: proposal and description of a novel entity","volume":"4","author":"De Gottardi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024122313404900300_bib27","doi-asserted-by":"crossref","first-page":"100811","DOI":"10.1016\/j.blre.2021.100811","article-title":"Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia","volume":"49","author":"Kuter","year":"2021","journal-title":"Blood Rev"},{"issue":"21","key":"2024122313404900300_bib28","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood.V116.21.1429.1429","article-title":"Platelet function and response to thrombopoietin mimetics in Wiskott-Aldrich syndrome\/X-linked thrombocytopenia","volume":"116","author":"Bussel","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2024122313404900300_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/MPH.0000000000001528","article-title":"Eltrombopag therapy in children with rare disorders associated with thrombocytopenia","volume":"42","author":"Fr\u0105czkiewicz","year":"2020","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"6","key":"2024122313404900300_bib30","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"2024122313404900300_bib31","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2249.2008.03711.x","article-title":"Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia","volume":"153","author":"Ward","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"2024122313404900300_bib34","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1006\/clim.1999.4799","article-title":"Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies)","volume":"93","author":"Conley","year":"1999","journal-title":"Clin Immunol"},{"key":"2024122313404900300_bib32","doi-asserted-by":"crossref","first-page":"846660","DOI":"10.3389\/fimmu.2022.846660","article-title":"Pathogenesis of autoimmune cytopenias in inborn errors of immunity revealing novel therapeutic targets","volume":"13","author":"Cortesi","year":"2022","journal-title":"Front Immunol"},{"issue":"23","key":"2024122313404900300_bib33","first-page":"2867","article-title":"Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study","volume":"141","author":"Guillet","year":"2023","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/24\/6171\/2345269\/blooda_adv-2024-014370-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/24\/6171\/2345269\/blooda_adv-2024-014370-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T13:41:15Z","timestamp":1734961275000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/24\/6171\/518009\/Efficacy-and-safety-of-TPO-receptor-agonists-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":34,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2024,12,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014370","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]}}}